Joseph Shulman
Chief Tech/Sci/R&D Officer chez RHYTHM PHARMACEUTICALS, INC.
Fortune : 1 300 $ au 31/03/2024
Profil
Joseph Shulman's current job is Chief Technical Officer at Rhythm Pharmaceuticals, Inc. His former jobs include Senior Vice President-Technical Operations at Ra Pharmaceuticals, Inc. and Senior Vice President-Global Technical Operations at Novelion Therapeutics, Inc. He holds an MBA from Boston University and an undergraduate degree from the University of Miami.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 21/03/2024 | 30 ( 0,00% ) | 1 300 $ | 31/03/2024 |
Postes actifs de Joseph Shulman
| Sociétés | Poste | Début |
|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 27/07/2020 |
Anciens postes connus de Joseph Shulman
| Sociétés | Poste | Fin |
|---|---|---|
| RA PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01/07/2020 |
| NOVELION THERAPEUTICS INC. | Chief Tech/Sci/R&D Officer | 01/07/2019 |
Formation de Joseph Shulman
| Boston University | Masters Business Admin |
| University of Miami | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| RHYTHM PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Ra Pharmaceuticals, Inc.
 Ra Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ra Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of peptide-based drugs. It uses Extreme Diversity platform that allows to produce synthetic macrocyclic peptides. The company was founded by James W. Broderick and Douglas A. Treco on June 27, 2008 and is headquartered in Cambridge, MA. | Health Technology |
Novelion Therapeutics, Inc.
 Novelion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Novelion Therapeutics, Inc. engaged in the development and commercialization of pharmaceuitical products. It focused in providing new standards of care for individuals living with rare diseases. The company was founded on February 3, 1981 and was headquartered in Vancouver, Canada. | Health Technology |
